Dr Susan Conroy was involved in establishing Therakind and subsequently appointed CEO overseeing day-to day business operations.

Leads strategy, identification and negotiation of key agreements and commercial opportunities.

Expert in identification, evaluation, management and commercialisation of pharmaceutical and biotechnology projects across multiple pharmaceutical areas.

Former consultant specialising in maximising scientific value to early start up programmes, technology transfer, medical affairs, commercial exploitation of existing products and an independent funding assessor of university start-up projects.

PhD in Molecular Biology and post-doctoral research in oncology at University College London.

Jackie joined Therakind in 2007 and has worked in the pharmaceutical industry more than 40 years including 35 years in regulatory affairs.

Significant experience in worldwide regulatory strategy, product development planning across a large number of therapeutic areas and all stages of product development, as well as co-ordination, preparation and review of worldwide regulatory submissions.

Expert in EU/US licensing procedures and pharmaceutical regulations, directives and guidelines including those relating to paediatrics.

Previously, 15 years at Beecham/SmithKline Beecham (now Glaxo SmithKline) initially working in Formulation Development and then in Global Regulatory Affairs where she was responsible for worldwide product registration. She has also worked in regulatory affairs for smaller pharmaceutical companies.

Louise joined Therakind with more than 20 years experience in pharmaceutical regulatory affairs and regulatory compliance.

Extensive knowledge of EU/US clinical trial regulations as well as medical device licensing procedures and regulations, directives and guidelines.

Facilitated regulatory authority inspections of both UK- and US-based investigator sites and GMP and device manufacturing facilities.

Significant experience in managing compliance programmes for all phases of global clinical trials and 10 years experience in pharmacovigilance for licensed and investigational medicinal products.

Samantha joined Therakind in 2014 as Financial Controller with responsibility over all aspects of the financial management of the company including planning and forecasting, internal control, statutory reporting and company secretarial duties.

Supports business development and plays a key role in negotiation and management of commercial partnerships.

Provides close counsel to CEO and the Board of Directors with timely and accurate information critical to the decision-making process and strategic direction of the company.

Finance specialist with proven track record in financial and management accounting and systems development within the software industry, and multi-sector across a number of high-profile clients.

Qualified Chartered Accountant with ‘Big 4’ training. Degree in Economics from Cambridge University.

Julie-Ann joined Therakind with over 20 years experience in pharmaceutical development and project management.

Extensive experience in management of all aspects of pharmaceutical development with specific expertise in outsourcing and managing CRO activities.

Expert in writing and compiling CMC components of regulatory packages with significant experience with EU, US, and Japanese programmes and has acted as a pharmaceutical expert for a number of EU submissions.

Previously Formulation Development Scientist for Rhone Poulenc Rorer (now Sanofi Aventis) and Director of Pharmaceutical Development at Vectura (previously Innovata Biomed) where she was responsible for early phase and late phase pharmaceutical development and commercialisation projects.

Degree in Pharmacy and PhD in pharmaceutical drug delivery from The University of Manchester.

Patricia joined Therakind in 2020 with more than 25 years of experience in providing regulatory affairs counsel to the pharmaceutical industry.

Expert in strategic planning of regulatory affairs, including defining the most appropriate European licensing route.

Significant experience in leading global project teams on strategic and operational regulatory aspects for compounds across a range of therapeutic areas and in all stages of development, licensing and post-licensing through the European Centralised, Decentralised and Mutual Recognition Procedures.

Previously, Regulatory Affairs Consultant to SmithKline Beecham, Glaxo Wellcome and Eli Lilly.

Qualified in medicine from University of London.